Bellevue Life Sciences Acquisition Corp. Announces Separate Trading of its Shares of Common Stock, Warrants and Rights Commencing March 17, 2023
The units were initially offered by the Company in an underwritten offering. Chardan acted as sole book-running manager of the offering.
A registration statement relating to the units and the underlying securities was declared effective by the
The Company is a blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, the Company intends to focus our search on companies in the healthcare industry.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements," including with respect to the anticipated separation of the units into shares of common stock, warrants and rights. No assurance can be given that the units will be separated as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus relating to the Company's initial public offering filed with the
Phone: +1 (206) 317-9114, Email: firstname.lastname@example.org
View original content:https://www.prnewswire.com/news-releases/bellevue-life-sciences-acquisition-corp-announces-separate-trading-of-its-shares-of-common-stock-warrants-and-rights-commencing-march-17-2023-301772041.html